Li Sen, Li Jiangtao, Yang Ping, Dong Fei, Liu Hui, Jing Hongmei
Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191 China.
Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730 China.
Indian J Hematol Blood Transfus. 2024 Apr;40(2):190-195. doi: 10.1007/s12288-023-01704-8. Epub 2023 Oct 17.
No consensus has been made on the use of PEG-modification recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in patients receiving autologous peripheral blood stem cell transplantation (PBSCT). To evaluate the efficacy and safety of PEG-rhG-CSF in provision of neutrophil support for lymphoma patients receiving autologous PBSCT. This retrospective study included lymphoma patients receiving either PEG-rhG-CSF or rhG-CSF after autologous PBSCT from 2018 to 2021 in two clinics. Hematologic recovery time, incidence of infectious complications and toxicity were compared between these two rhG-CSFs and among different initiation time of PEG-rhG-CSF. Of the 139 subjects included, 93 received PEG-rhG-CSF and 46 received rhG-CSF after transplantation. Compared with rhG-CSF, PEG-rhG-CSF marginally but significantly accelerated the neutrophil engraftment by 1 day (10 vs. 9 days, respectively) with no increasing on the risk of infectious complication and toxicity. In the PEG-rhG-CSF group, 50 patients received the growth factor on day 1, 19 received on day 3 and 24 received on day 5. The neutrophil engraftment was significantly shorter in day 1 and day 3 subgroup (9, 9, and 10 days, respectively), with a lower incidence of febrile neutropenia (82%, 100%, 100%) and documented infections (76%, 100%, 100%) in day 1 subgroup. PEG-rhG-CSF might be an alternative to rhG-CSF for lymphoma patients received autologous PBSCT. Administrating PEG-rhG-CSF on day 1 can achieve both faster hematologic recovery and lower infectious complications.
The online version contains supplementary material available at 10.1007/s12288-023-01704-8.
对于接受自体外周血干细胞移植（PBSCT）的患者使用聚乙二醇修饰重组人粒细胞集落刺激因子（PEG-rhG-CSF），目前尚未达成共识。为了评估PEG-rhG-CSF为接受自体PBSCT的淋巴瘤患者提供中性粒细胞支持的有效性和安全性。这项回顾性研究纳入了2018年至2021年在两家诊所接受自体PBSCT后使用PEG-rhG-CSF或rhG-CSF的淋巴瘤患者。比较了这两种rhG-CSF之间以及PEG-rhG-CSF不同起始时间的血液学恢复时间、感染并发症发生率和毒性。在纳入的139名受试者中，93名在移植后接受了PEG-rhG-CSF，46名接受了rhG-CSF。与rhG-CSF相比，PEG-rhG-CSF使中性粒细胞植入略微但显著加快了1天（分别为10天和9天），且感染并发症和毒性风险没有增加。在PEG-rhG-CSF组中，50名患者在第1天接受生长因子，19名在第3天接受，24名在第5天接受。第1天和第3天亚组的中性粒细胞植入明显更短（分别为9天、9天和10天），第1天亚组的发热性中性粒细胞减少发生率（分别为82%、100%、100%）和有记录的感染发生率（分别为76%、100%、100%）更低。对于接受自体PBSCT的淋巴瘤患者，PEG-rhG-CSF可能是rhG-CSF的替代选择。在第1天给予PEG-rhG-CSF可以实现更快的血液学恢复和更低的感染并发症。
在线版本包含可在10.1007/s12288-023-01704-8获取的补充材料。
